---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Explore-OSA"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Explore-OSA. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/explore-osa"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Explore-OSA

<a id="heading-3.1.6"></a>

## 3.1.6 Explore-OSA

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.”
> “A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.1-2"></a>

#### Objective stated in the congress abstract

> “To investigate the efficacy and safety of lorundrostat in adults with moderate-to-severe OSA and uHTN.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.1-3"></a>

#### Hypothesis stated by the sponsor at trial initiation

> “The key objective of this trial is to validate the hypothesis that lorundrostat both alleviates the severity of upper airway obstruction and reduces nocturnal hypertension.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.1-4"></a>

#### Proof-of-concept purpose stated by the sponsor

> “This proof-of-concept trial was designed to evaluate the efficacy, safety, and tolerability of lorundrostat in overweight or obese adults with moderate-to-severe OSA and hypertension.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual)”
> “2025-02-28”
> “Primary Completion (Actual)”
> “2025-12-17”
> “Study Completion (Actual)”
> “2025-12-29”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.2-2"></a>

#### Registered locations

> “This study has 27 locations”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.2-3"></a>

#### Planned number of sites at trial initiation

> “Subjects will be at least 18 years old, with a BMI ≥27 kg/m2, and the trial will be conducted across approximately 40 sites.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.2-4"></a>

#### Other study identifiers

> “MLS-101-207”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.2-5"></a>

#### Results reporting status in the ClinicalTrials.gov record

> “Certification/Extension First Submitted”
> “2026-08-17”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Randomized, double-blind, placebo-controlled crossover design in the congress abstract

> “The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover trial in 47 participants with body mass index (BMI) ≥27 kg/m2, apnea-hypopnea index (AHI) ≥15 events/hour, and SBP ≥130 to <180/diastolic BP ≥60 to ≤110 mmHg.”
> “Participants were randomized to one of two treatment sequences: active treatment with lorundrostat 50 mg daily for 4 weeks/2-week washout/placebo for 4 weeks or placebo for 4 weeks/washout/active treatment for 4 weeks.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.3-2"></a>

#### Study periods in the ClinicalTrials.gov record

> “The study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.3-3"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “48” |

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.3-4"></a>

#### Exploratory two-period, two-sequence design described by the sponsor

> “The Explore-OSA trial was a Phase 2, randomized, double-blind, placebo-controlled, two-period, two-sequence (2x2) crossover, exploratory trial that evaluated the safety and efficacy of lorundrostat 50 mg QD administered in the evening in 48 participants with hypertension and moderate-to-severe OSA.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-3.1.6.3-5"></a>

#### Blood pressure monitoring during polysomnography

> “Participants in Explore-OSA received 50 mg of oral, once daily (QD) lorundrostat and placebo in sequential treatment periods, with continuous monitoring of BP during overnight polysomnography.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Key eligibility criteria in the congress abstract

> “The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover trial in 47 participants with body mass index (BMI) ≥27 kg/m2, apnea-hypopnea index (AHI) ≥15 events/hour, and SBP ≥130 to <180/diastolic BP ≥60 to ≤110 mmHg.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.4-2"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Body mass index (BMI) ≥ 27 kilograms per meter square (kg/m^2)”
> “Previously diagnosed with moderate-to-severe OSA”
> “AHI ≥15 events per hour (/hr) prior to Randomization”
> “AOBP SBP of ≥130 and less than or equal to (≤) 180 millimeter of mercury (mmHg) and AOBP diastolic blood pressure (DBP) ≥60 and ≤110 mmHg”
> “Participants on CPAP or PAP therapy are eligible provided they are on PAP for ≥4 hours per night (documented) and for at least 3 months prior to the study enrollment (documented)”
> “Participants not currently on PAP therapy, and not anticipated to start PAP for the duration of the study”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.4-3"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit or history of diabetic ketoacidosis in the 6 months prior to the Screening Visit”
> “Participants on a glucagon-like peptide-1 (GLP-1) agonist.”
> “Have diagnosis of central or mixed sleep apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration”
> “Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia”
> “Use of bilevel positive airway pressure (BiPAP) therapy.”
> “eGFR less than (<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) at Screening using serum creatinine or cystatin-C”
> “Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1 month of the Screening Visit”
> “Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6 months prior to Screening”
> “Previously diagnosed, recurrent orthostatic hypotension”
> “Current night-shift worker or anticipated to become a night-shift worker for 3 days continuously during the duration of the study.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.4-4"></a>

#### Ages eligible in the ClinicalTrials.gov record

> “18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Lorundrostat 50 mg or placebo once daily in the evening

> “After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the apnea-hypopnea index (AHI), the primary endpoint.”
> “Participants in Explore-OSA received 50 mg of oral, once daily (QD) lorundrostat and placebo in sequential treatment periods, with continuous monitoring of BP during overnight polysomnography.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.5-2"></a>

#### Treatment sequences in the congress abstract

> “Participants were randomized to one of two treatment sequences: active treatment with lorundrostat 50 mg daily for 4 weeks/2-week washout/placebo for 4 weeks or placebo for 4 weeks/washout/active treatment for 4 weeks.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.5-3"></a>

#### Interventions and positive airway pressure use in the ClinicalTrials.gov record

> “Lorundrostat tablet.”
> “Lorundrostat matching placebo tablet.”
> “Participants on PAP therapy should comply with PAP therapy for the duration of the study.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Apnea-Hypopnea Index as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Primary endpoint

> “The primary endpoint was the difference in change in AHI during placebo and active treatment.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-2"></a>

##### Registered primary outcome measure

> “Placebo-adjusted Change From Baseline in AHI at Week 4”
> “Baseline, Week 4”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.6.1-3"></a>

##### Primary endpoint definition stated by the sponsor

> “The primary efficacy endpoint of the trial was absolute change from baseline in apnea-hypopnea index (AHI) after four weeks of active treatment compared to placebo.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.6.1-4"></a>

##### Sponsor rationale for an effect on upper airway obstruction

> “The primary outcome measure is absolute change in the frequency of apnea-hypopnea episodes.”
> “In addition, lorundrostat is anticipated to reduce the severity of upper airway obstruction and associated OSA symptoms such as daytime sleepiness and cognitive impairment.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.6.1-5"></a>

##### Investigator rationale for aldosterone synthase inhibition in obstructive sleep apnea

> “Obesity and OSA promote aldosterone excess, contributing to resistant hypertension and upper airway edema, yet mineralocorticoid receptor antagonists (MRAs) are infrequently prescribed in patients with OSA.”
> “Lorundrostat, a highly selective aldosterone synthase inhibitor (ASI), may restore aldosterone homeostasis and lower blood pressure while also ameliorating OSA.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-6"></a>

##### Apnea-hypopnea index as the most studied measure of sleep apnea severity

> “OSA has well established cardiovascular and neurocognitive sequelae, although the optimal metric to assess its severity and/or potential response to therapy remains unclear.”
> “The apnea-hypopnea index (AHI) is well established; thus, we review its history and predictive value in various different clinical contexts.”
> “Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="topic-3.1.6.6.1-7"></a>

##### Severity thresholds based on the apnea-hypopnea index

> “Moderate OSA is defined as having between 15 and 30 breathing pauses (apnea or hypopnea events) per hour of sleep, while severe OSA indicates more than 30 breathing pauses per hour.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.6.1-8"></a>

##### Apnea-hypopnea index as the primary endpoint of the trials supporting an approved obstructive sleep apnea indication

> “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”
> “Moderate OSA was defined as an AHI ≥15 – 30 events/hour on polysomnogram at baseline.”
> “Severe OSA was defined as an AHI ≥30 events/hour on polysomnogram at baseline.”
> “The primary endpoint for Studies 5 and 6 was the change from baseline in the apnea-hypopnea index (AHI) at Week 52.”

Source: [Eli Lilly ZEPBOUND prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf)

<a id="topic-3.1.6.6.1-9"></a>

##### Apnea-hypopnea index as a phase 3 primary endpoint

> “The primary end point was the change in the apnea–hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.”
> “The AHI was measured by laboratory polysomnography at screening, week 20, and week 52.”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-3.1.6.6.1-10"></a>

##### Key secondary endpoint: office systolic blood pressure

> “The key secondary endpoint was difference in change in morning office SBP. Additional endpoints included the Functional Outcomes of Sleep Questionnaire (FOSQ)-10.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-11"></a>

##### Secondary endpoints stated by the sponsor

> “The first secondary endpoint was AOBP, and additional endpoints were nighttime BP and sleep and cardiovascular health measures.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.6.1-12"></a>

##### Key secondary objective stated at trial initiation

> “The key secondary objective is to quantify blood pressure throughout the night using continuous BP monitoring during performance of a standard sleep study without the benefit of CPAP. Standard patient reported outcomes, specific to OSA will also be assessed.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.6.1-13"></a>

##### Registered secondary outcome measures

> “Placebo-adjusted Change From Baseline in Nighttime Average Systolic Blood Pressure (SBP) at Week 4”
> “Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) SBP at Week 4”
> “Placebo-adjusted Change From Baseline in Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10) at Week 4”
> “Placebo-adjusted Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 4”
> “Placebo-adjusted Change From Baseline in Patient-Reported Outcomes Measurement Information System - Sleep Disturbance (PROMIS-SD) at Week 4”
> “Placebo-adjusted Change From Baseline in PROMIS Sleep-Related Impairment (SRI) at Week 4”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.6.1-14"></a>

##### Rationale for blood pressure endpoints in obstructive sleep apnea

> “Uncontrolled hypertension (uHTN), a major driver of adverse cardiovascular (CV) outcomes, affects up to 80% of patients with obstructive sleep apnea (OSA).”
> “While established OSA therapies such as positive airway pressure (PAP), hypoglossal nerve stimulation, and mandibular advancement devices can effectively restore upper airway patency, their effect on systolic blood pressure (SBP) reduction is generally modest (<5 mmHg).”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-15"></a>

##### Systolic blood pressure reduction and major cardiovascular events

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Planned enrollment at trial initiation

> “The planned Phase 2 clinical trial is a placebo-controlled, crossover study to evaluate the safety and efficacy of lorundrostat 50mg taken once daily in the evening in approximately 40 subjects with moderate-to-severe OSA.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.7.1-2"></a>

##### Enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual)”
> “48”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.7.1-3"></a>

##### Participants reported in the topline release

> “The Explore-OSA trial was a Phase 2 exploratory trial of lorundrostat in forty-eight participants with an average body mass index (BMI) of 38.2 kg/m2, an average apnea-hypopnea index (AHI) of 48.5 events/hr and an average systolic blood pressure (BP) of 142.3 mmHg (range 131-175 mmHg).”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.7.1-4"></a>

##### Participants reported in the congress abstract

> “The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover trial in 47 participants with body mass index (BMI) ≥27 kg/m2, apnea-hypopnea index (AHI) ≥15 events/hour, and SBP ≥130 to <180/diastolic BP ≥60 to ≤110 mmHg.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Parallel-arm and crossover analyses

> “In a preplanned parallel arm analysis of the first treatment period providing a point estimate of efficacy, the placebo-adjusted reduction in SBP with lorundrostat was 10.1 mmHg (P=0.0089).”
> “In the crossover analysis of both treatment periods, the placebo-adjusted reduction in SBP was 6.2 mmHg (P<0.0003).”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.7.2-2"></a>

##### Topline status of the March 2026 analysis

> “Analysis is ongoing for other endpoints in the trial and will be reported in future publications or medical meetings.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Body mass index, apnea-hypopnea index, and systolic blood pressure at baseline

> “The Explore-OSA trial was a Phase 2 exploratory trial of lorundrostat in forty-eight participants with an average body mass index (BMI) of 38.2 kg/m2, an average apnea-hypopnea index (AHI) of 48.5 events/hr and an average systolic blood pressure (BP) of 142.3 mmHg (range 131-175 mmHg).”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.2-2"></a>

##### Positive airway pressure use

> “The Explore-OSA trial, in which more than a third of participants were using PAP therapy, did not demonstrate a difference in AHI response between lorundrostat- and placebo-treated participants.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Summary: systolic blood pressure figures in the congress abstract and the company releases

The congress abstract reports the preplanned parallel-arm analysis of the first treatment period as a placebo-adjusted reduction in systolic blood pressure of 10.1 mmHg (P=0.0089). The NDA acceptance release and the AHA Hypertension 2026 release report within-group reductions of 11.1 mmHg with lorundrostat (p<0.0001) and 1.0 mmHg with placebo (p=NS) at week 4, and the NDA acceptance release attributes these figures to the pre-planned parallel arm analysis of the first period; the difference between the two within-group figures is 10.1 mmHg. The abstract and the NDA acceptance release both report a placebo-adjusted reduction of 6.2 mmHg (P<0.0003) in the crossover analysis of both treatment periods. The NDA acceptance release reports topline results.

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08); [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for); [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="topic-3.1.6.8.3-2"></a>

##### Primary endpoint: apnea-hypopnea index not met

> “There was no difference in AHI response between lorundrostat- and placebo-treated participants.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.3-3"></a>

##### Primary endpoint result in the topline release

> “After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the apnea-hypopnea index (AHI), the primary endpoint.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.3-4"></a>

##### Office systolic blood pressure: placebo-adjusted estimates in the congress abstract

> “In a preplanned parallel arm analysis of the first treatment period providing a point estimate of efficacy, the placebo-adjusted reduction in SBP with lorundrostat was 10.1 mmHg (P=0.0089).”
> “In the crossover analysis of both treatment periods, the placebo-adjusted reduction in SBP was 6.2 mmHg (P<0.0003).”
> “A clinically meaningful reduction in office SBP in adults with moderate-to-severe OSA and hypertension was seen, with similar magnitude compared with prior pivotal lorundrostat treatment trials in patients with uHTN.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.3-5"></a>

##### Office systolic blood pressure: within-group changes and crossover estimate in the topline release

> “At week four, the trial demonstrated an 11.1 mmHg (p < 0.0001) and a 1.0 mmHg (p = NS) BP reduction with lorundrostat and placebo, respectively, in the pre-planned parallel arm analysis of the first period. There was a 6.2 mmHg placebo-adjusted reduction (p < 0.0003) in BP in the crossover analysis.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.3-6"></a>

##### Final results reported by the sponsor

> “Participants receiving lorundrostat 50 mg once daily in the evening achieved clinically meaningful reductions in morning SBP of 11.1 mmHg at Week 4 (p<0.0001), compared with 1.0 mmHg reduction for participants receiving placebo (p=NS), although no measurable change in apnea-hypopnea indices were observed with lorundrostat.”

Source: [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="topic-3.1.6.8.3-7"></a>

##### Nighttime blood pressure

No evidence found.

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

##### Functional Outcomes of Sleep Questionnaire-10

> “Changes in FOSQ-10 were not observed.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.4-2"></a>

##### Epworth Sleepiness Scale and PROMIS sleep measures

No evidence found.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Serious adverse events and tolerability in the congress abstract

> “There were no serious adverse events reported (Table 2).”
> “Lorundrostat was well tolerated.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.5-2"></a>

##### Serum potassium in the topline release

> “Lorundrostat demonstrated a favorable safety profile and was well tolerated, with no serum potassium excursions above 5.5 mmol/L.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.5-3"></a>

##### Safety in the final results release

> “In the study, lorundrostat exhibited a favorable safety and tolerability profile, and there was no evidence of significant safety events, including hyperkalemia (high serum potassium).”

Source: [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary

Explore-OSA was a phase 2 crossover trial with two 4-week treatment periods separated by a 2-week washout; the registry lists 48 enrolled participants and the congress abstract describes 47. The primary endpoint, the placebo-adjusted change in apnea-hypopnea index at week 4, showed “no difference in AHI response between lorundrostat- and placebo-treated participants”. Office systolic blood pressure was a secondary endpoint, and the public results come from a congress abstract and company releases; no peer-reviewed publication or posted registry results were located, and the registry record shows a certification/extension submission dated 2026-08-17. The registry lists nighttime average systolic blood pressure as the first secondary outcome measure and also lists the Epworth Sleepiness Scale and two PROMIS sleep measures; no result for any of these was located in the public documents. The parallel-arm systolic blood pressure estimate uses the first treatment period alone, and the abstract and the company releases state it differently. The abstract states that “more than a third of participants were using PAP therapy”. Public safety reporting is limited to the absence of serious adverse events and of serum potassium values above 5.5 mmol/L. Eligibility excluded participants with eGFR below 45 mL/min/1.73 m2 and participants taking a GLP-1 agonist, and the registry lists 27 locations.

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08); [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454); [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.9-2"></a>

#### Conclusions stated by the investigators

> “The Explore-OSA trial, in which more than a third of participants were using PAP therapy, did not demonstrate a difference in AHI response between lorundrostat- and placebo-treated participants.”
> “Given the high prevalence of aldosterone dysregulation and its association with cardiometabolic disease in OSA, a longer-term CV outcomes trial of lorundrostat should be considered.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.9-3"></a>

#### Topline status of the March 2026 results

> “topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
